We’re delighted to share the news of two important updates to reMYND’s management team, with the appointment of Floor Stam as CEO and Johan Cardoen as Chairman of the Board. Read the full release here: Welcome, Floor, Johan! #newhire #drugdiscovery

Tomorrow at AAIC in Philadelphia, Wannes will be presenting a poster outlining findings on the relevance of the APP Knock-In mouse model in Alzheimer’s research. If you would like to meet Wannes in Philadelphia, please email: cro@remynd.com. #AAIC2024 #reMYND #research

We're heading to #AAIC2024 in Philadelphia next week. Our Chief Scientific Officer, Gerard Griffioen, will be in attendance. If you would like to connect with Gerard, please email us at bd@remynd.com #reMYND #Biotech #Alzheimers

Preclinical #research on septin modulators identified by reMYND has been published today in @ScienceMagazine, outlining the neuroprotective qualities of these septin modulators, which has implications for the treatment of #Alzheimers. Read more here:

We are currently in San Sebastian, attending the 24th #BioEquityEurope conference. We look forward to spending time with fellow industry leaders and investors and gaining insights on the outlook for the #biotech sector. @BioCentury @EBDgroup #BEE24

It is the third day of the AD/PD conference and our CRO Science Director, Tom Cornelissen, will be giving an oral presentation on the strengthening of the APP SAA’s relevance as a tool in preclinical studies. #reMYND #Alzheimers #drugdiscovery #ADPD2024

Today, our CRO Science Director, Tom Cornelissen, and our CRO Study Director, Sofie Carmans, will be presenting two posters at the AD/PD conference in Lisbon. #reMYND #Alzheimers #Conferences #APDP2024

As 2023 comes to a close, we look back on very busy year! Thank you to everyone at reMYND for their hard work this year, and roll on 2024! #drugdiscovery #innovation #Alzheimers #reMYND

#DYK that there is one new case of dementia every 3.2 seconds. reMYND’s lead ReS19-T program aims to address the root of Alzheimer’s and restore synaptic plasticity, rather than just treating symptoms. #Alzheimers #drugdiscovery #reMYND #biotech #NeurodegenerativeDiseases

It’s been a busy time so far at The Society for Neuroscience conference! At 3:00pm is giving an oral presentation on reMYND’s novel APP SAA mouse model, which includes data from our lead ReS19-T compound. #reMYND #Alzheimers #biotech

We are in Washington D.C today for the Society for Neuroscience conference! reMYND’s Tom Cornelissen has already presented a poster of our Parkinson’s model and will give a talk on compound intervention in an APP knock-in model Tuesday at 3:00 PM #reMYND #conference #biotech

We’re looking forward to the start of the Society of Neuroscience conference, kicking off this Saturday. Tom Cornelissen, CRO Science Director, will be sharing the latest CRO updates in an oral presentation and a poster. #reMYND #conference #biotech

Today marks the start of the 2023 #CTAD conference in Boston! Our Managing Director, Koen De Witte is attending and looks forward to connecting with fellow experts in the field over the coming days. For a meeting, reach out to bd@remynd.com #reMYND #Alzheimers #Conference

We will be in Boston next week for the #CTAD conference. Our Managing Director, Koen De Witte, will be in attendance and looks forward to meeting other leaders in Alzheimer’s.

It was valuable time spent last week at #BioJapan2023, our thanks to the organisers, @flandersbio and @FlandersTrade Tokyo! During the Flanders Life Sciences seminar, reMYND’s Business Scientist Wannes Dejonckheere shared details on the #reMYND 's CRO expertise.

We're glad to be part of a team with diverse disciplines, each providing their unique insights! @VIBLifeSciences @KU_Leuven @imecVlaanderen @ONTOFORCE @hict_consulting with support from @VLAIO_be

So much more needs to be done in both the diagnosis and treatment. Read more on our ongoing research here:

We continue to look for novel solutions to treat neurodegenerative diseases, including Alzheimer’s, with our lead Alzheimer’s program currently in clinical trials. #ReduceRiskNow #reMYND #alzheimersdisease